Synergistic effect of non-transmissible Sendai virus vector encoding the c-myc suppressor FUSE-binding protein-interacting repressor plus cisplatin in the treatment of malignant pleural mesothelioma

Atsushi Kitamura, Kazuyuki Matsushita, Yuichi Takiguchi, Hideaki Shimada, Yuji Tada, Makako Yamanaka, Kenzo Hiroshima, Masatoshi Tagawa, Takeshi Tomonaga, Hisahiro Matsubara, Makoto Inoue, Mamoru Hasegawa, Yasunori Sato, David Levens, Koichiro Tatsumi, Fumio Nomura

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Human malignant pleural mesothelioma (HMPM) is highly resistant to conventional therapy, and therefore novel therapies are required. We previously reported that overexpression of the FUSE-binding protein-interacting repressor (FIR), a c-myc transcriptional repressor, induces apoptosis via c-Myc suppression, and is thus a suitable cancer therapy. In the current preclinical trial, a fusion gene deleted non-transmissible Sendai virus vector encoding FIR (SeV/ΔF/FIR) was prepared and its cytotoxic activity against an orthotopic xenograft model of HMPM, in combination with cisplatin, was assessed. SeV/ΔF/FIR and a fusion gene deleted non-transmissible Sendai virus vector encoding green fluorescent protein (SeV/ΔF/GFP) were prepared. The transduction efficiency of these agents in terms of dose-dependent cytotoxicity and/or apoptosis induction was then assessed in a few HMPM cells. Combination therapy with SeV/ΔF/FIR plus cisplatin was evaluated in vitro and in a mouse model. SeV/ΔF/FIR significantly reduced cell viability in three HMPM cell lines but was less effective in non-tumor immortalized mesothelial cells. SeV/ΔF/FIR cytotoxicity was partly due to apoptosis induction via c-Myc suppression. In addition, SeV/ΔF/FIR showed synergistic antitumor effects in combination with cisplatin, as was revealed by isobologram analysis in MSTO-211H. Moreover, combination therapy with SeV/ΔF/FIR plus cisplatin demonstrated significant tumor reduction and improvement in survival rate in an animal model. Combination therapy with SeV/ΔF/FIR plus cisplatin has therapeutic potential against HMPM. SeV/ΔF/FIR plus cisplatin will be an attractive modality against HMPM in the future.

Original languageEnglish
Pages (from-to)1366-1373
Number of pages8
JournalCancer Science
Volume102
Issue number7
DOIs
Publication statusPublished - 2011 Jul 1
Externally publishedYes

Fingerprint

Sendai virus
Cisplatin
Gene Fusion
Apoptosis
Therapeutics
poly-U binding splicing factor 60KDa
Malignant Mesothelioma
Green Fluorescent Proteins
Heterografts
Neoplasms
Cell Survival
Animal Models

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Synergistic effect of non-transmissible Sendai virus vector encoding the c-myc suppressor FUSE-binding protein-interacting repressor plus cisplatin in the treatment of malignant pleural mesothelioma. / Kitamura, Atsushi; Matsushita, Kazuyuki; Takiguchi, Yuichi; Shimada, Hideaki; Tada, Yuji; Yamanaka, Makako; Hiroshima, Kenzo; Tagawa, Masatoshi; Tomonaga, Takeshi; Matsubara, Hisahiro; Inoue, Makoto; Hasegawa, Mamoru; Sato, Yasunori; Levens, David; Tatsumi, Koichiro; Nomura, Fumio.

In: Cancer Science, Vol. 102, No. 7, 01.07.2011, p. 1366-1373.

Research output: Contribution to journalArticle

Kitamura, A, Matsushita, K, Takiguchi, Y, Shimada, H, Tada, Y, Yamanaka, M, Hiroshima, K, Tagawa, M, Tomonaga, T, Matsubara, H, Inoue, M, Hasegawa, M, Sato, Y, Levens, D, Tatsumi, K & Nomura, F 2011, 'Synergistic effect of non-transmissible Sendai virus vector encoding the c-myc suppressor FUSE-binding protein-interacting repressor plus cisplatin in the treatment of malignant pleural mesothelioma', Cancer Science, vol. 102, no. 7, pp. 1366-1373. https://doi.org/10.1111/j.1349-7006.2011.01931.x
Kitamura, Atsushi ; Matsushita, Kazuyuki ; Takiguchi, Yuichi ; Shimada, Hideaki ; Tada, Yuji ; Yamanaka, Makako ; Hiroshima, Kenzo ; Tagawa, Masatoshi ; Tomonaga, Takeshi ; Matsubara, Hisahiro ; Inoue, Makoto ; Hasegawa, Mamoru ; Sato, Yasunori ; Levens, David ; Tatsumi, Koichiro ; Nomura, Fumio. / Synergistic effect of non-transmissible Sendai virus vector encoding the c-myc suppressor FUSE-binding protein-interacting repressor plus cisplatin in the treatment of malignant pleural mesothelioma. In: Cancer Science. 2011 ; Vol. 102, No. 7. pp. 1366-1373.
@article{f9a015d5f4bd43938b7d2e006d89bb78,
title = "Synergistic effect of non-transmissible Sendai virus vector encoding the c-myc suppressor FUSE-binding protein-interacting repressor plus cisplatin in the treatment of malignant pleural mesothelioma",
abstract = "Human malignant pleural mesothelioma (HMPM) is highly resistant to conventional therapy, and therefore novel therapies are required. We previously reported that overexpression of the FUSE-binding protein-interacting repressor (FIR), a c-myc transcriptional repressor, induces apoptosis via c-Myc suppression, and is thus a suitable cancer therapy. In the current preclinical trial, a fusion gene deleted non-transmissible Sendai virus vector encoding FIR (SeV/ΔF/FIR) was prepared and its cytotoxic activity against an orthotopic xenograft model of HMPM, in combination with cisplatin, was assessed. SeV/ΔF/FIR and a fusion gene deleted non-transmissible Sendai virus vector encoding green fluorescent protein (SeV/ΔF/GFP) were prepared. The transduction efficiency of these agents in terms of dose-dependent cytotoxicity and/or apoptosis induction was then assessed in a few HMPM cells. Combination therapy with SeV/ΔF/FIR plus cisplatin was evaluated in vitro and in a mouse model. SeV/ΔF/FIR significantly reduced cell viability in three HMPM cell lines but was less effective in non-tumor immortalized mesothelial cells. SeV/ΔF/FIR cytotoxicity was partly due to apoptosis induction via c-Myc suppression. In addition, SeV/ΔF/FIR showed synergistic antitumor effects in combination with cisplatin, as was revealed by isobologram analysis in MSTO-211H. Moreover, combination therapy with SeV/ΔF/FIR plus cisplatin demonstrated significant tumor reduction and improvement in survival rate in an animal model. Combination therapy with SeV/ΔF/FIR plus cisplatin has therapeutic potential against HMPM. SeV/ΔF/FIR plus cisplatin will be an attractive modality against HMPM in the future.",
author = "Atsushi Kitamura and Kazuyuki Matsushita and Yuichi Takiguchi and Hideaki Shimada and Yuji Tada and Makako Yamanaka and Kenzo Hiroshima and Masatoshi Tagawa and Takeshi Tomonaga and Hisahiro Matsubara and Makoto Inoue and Mamoru Hasegawa and Yasunori Sato and David Levens and Koichiro Tatsumi and Fumio Nomura",
year = "2011",
month = "7",
day = "1",
doi = "10.1111/j.1349-7006.2011.01931.x",
language = "English",
volume = "102",
pages = "1366--1373",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Synergistic effect of non-transmissible Sendai virus vector encoding the c-myc suppressor FUSE-binding protein-interacting repressor plus cisplatin in the treatment of malignant pleural mesothelioma

AU - Kitamura, Atsushi

AU - Matsushita, Kazuyuki

AU - Takiguchi, Yuichi

AU - Shimada, Hideaki

AU - Tada, Yuji

AU - Yamanaka, Makako

AU - Hiroshima, Kenzo

AU - Tagawa, Masatoshi

AU - Tomonaga, Takeshi

AU - Matsubara, Hisahiro

AU - Inoue, Makoto

AU - Hasegawa, Mamoru

AU - Sato, Yasunori

AU - Levens, David

AU - Tatsumi, Koichiro

AU - Nomura, Fumio

PY - 2011/7/1

Y1 - 2011/7/1

N2 - Human malignant pleural mesothelioma (HMPM) is highly resistant to conventional therapy, and therefore novel therapies are required. We previously reported that overexpression of the FUSE-binding protein-interacting repressor (FIR), a c-myc transcriptional repressor, induces apoptosis via c-Myc suppression, and is thus a suitable cancer therapy. In the current preclinical trial, a fusion gene deleted non-transmissible Sendai virus vector encoding FIR (SeV/ΔF/FIR) was prepared and its cytotoxic activity against an orthotopic xenograft model of HMPM, in combination with cisplatin, was assessed. SeV/ΔF/FIR and a fusion gene deleted non-transmissible Sendai virus vector encoding green fluorescent protein (SeV/ΔF/GFP) were prepared. The transduction efficiency of these agents in terms of dose-dependent cytotoxicity and/or apoptosis induction was then assessed in a few HMPM cells. Combination therapy with SeV/ΔF/FIR plus cisplatin was evaluated in vitro and in a mouse model. SeV/ΔF/FIR significantly reduced cell viability in three HMPM cell lines but was less effective in non-tumor immortalized mesothelial cells. SeV/ΔF/FIR cytotoxicity was partly due to apoptosis induction via c-Myc suppression. In addition, SeV/ΔF/FIR showed synergistic antitumor effects in combination with cisplatin, as was revealed by isobologram analysis in MSTO-211H. Moreover, combination therapy with SeV/ΔF/FIR plus cisplatin demonstrated significant tumor reduction and improvement in survival rate in an animal model. Combination therapy with SeV/ΔF/FIR plus cisplatin has therapeutic potential against HMPM. SeV/ΔF/FIR plus cisplatin will be an attractive modality against HMPM in the future.

AB - Human malignant pleural mesothelioma (HMPM) is highly resistant to conventional therapy, and therefore novel therapies are required. We previously reported that overexpression of the FUSE-binding protein-interacting repressor (FIR), a c-myc transcriptional repressor, induces apoptosis via c-Myc suppression, and is thus a suitable cancer therapy. In the current preclinical trial, a fusion gene deleted non-transmissible Sendai virus vector encoding FIR (SeV/ΔF/FIR) was prepared and its cytotoxic activity against an orthotopic xenograft model of HMPM, in combination with cisplatin, was assessed. SeV/ΔF/FIR and a fusion gene deleted non-transmissible Sendai virus vector encoding green fluorescent protein (SeV/ΔF/GFP) were prepared. The transduction efficiency of these agents in terms of dose-dependent cytotoxicity and/or apoptosis induction was then assessed in a few HMPM cells. Combination therapy with SeV/ΔF/FIR plus cisplatin was evaluated in vitro and in a mouse model. SeV/ΔF/FIR significantly reduced cell viability in three HMPM cell lines but was less effective in non-tumor immortalized mesothelial cells. SeV/ΔF/FIR cytotoxicity was partly due to apoptosis induction via c-Myc suppression. In addition, SeV/ΔF/FIR showed synergistic antitumor effects in combination with cisplatin, as was revealed by isobologram analysis in MSTO-211H. Moreover, combination therapy with SeV/ΔF/FIR plus cisplatin demonstrated significant tumor reduction and improvement in survival rate in an animal model. Combination therapy with SeV/ΔF/FIR plus cisplatin has therapeutic potential against HMPM. SeV/ΔF/FIR plus cisplatin will be an attractive modality against HMPM in the future.

UR - http://www.scopus.com/inward/record.url?scp=79959280743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959280743&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2011.01931.x

DO - 10.1111/j.1349-7006.2011.01931.x

M3 - Article

C2 - 21435101

AN - SCOPUS:79959280743

VL - 102

SP - 1366

EP - 1373

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 7

ER -